At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4556 Gene Editing
Closed 02-03 16:00:00 EST
452.21
+0.31
+0.07%
High466.92Low438.89Vol35.60M
Open452.55D1 Closing451.90Amplitude6.20%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O166.92MT/O Rate--Tradable Shares0.00
P/B2.571084ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Sangamo Therapeutics stellt positive Phase-1/2-Studienergebnisse für Gentherapie bei Fabry-Krankheit vor
Reuters  ·  05:09
Sangamo Therapeutics stellt positive Phase-1/2-Studienergebnisse für Gentherapie bei Fabry-Krankheit vor
Sangamo Therapeutics Begins Rolling BLA Submission to FDA for Fabry Disease Gene Therapy
Reuters  ·  05:09
Sangamo Therapeutics Begins Rolling BLA Submission to FDA for Fabry Disease Gene Therapy
BUZZ-U.S. STOCKS ON THE MOVE-Western Digital, Broadridge, WTW
Reuters  ·  00:02
BUZZ-U.S. STOCKS ON THE MOVE-Western Digital, Broadridge, WTW
Sangamo says principal financial officer Prathyusha Duraibabu terminated
TIPRANKS  ·  02-03 22:22
Sangamo says principal financial officer Prathyusha Duraibabu terminated
Sangamo names Nikunj Jain as interim CFO, principal financial officer
TIPRANKS  ·  02-03 22:21
Sangamo names Nikunj Jain as interim CFO, principal financial officer
Sangamo prices 35.2M shares at 47.19c in underwritten offering
TIPRANKS  ·  02-03 22:15
Sangamo prices 35.2M shares at 47.19c in underwritten offering
Sangamo Therapeutics Prices $25 Million Offering with Warrants and Share Rights
Reuters  ·  02-03 22:10
Sangamo Therapeutics Prices $25 Million Offering with Warrants and Share Rights
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
THOMSON REUTERS  ·  02-03 22:10
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
BRIEF-Sangamo Therapeutics Inc - On Feb 2, Prathyusha Duraibabu Terminated As Principal Financial Officer - SEC Filing
Reuters  ·  02-03 22:03
BRIEF-Sangamo Therapeutics Inc - On Feb 2, Prathyusha Duraibabu Terminated As Principal Financial Officer - SEC Filing
Sangamo Therapeutics Inc - on Feb 2, Prathyusha Duraibabu Terminated as Principal Financial Officer - SEC Filing
THOMSON REUTERS  ·  02-03 21:57
Sangamo Therapeutics Inc - on Feb 2, Prathyusha Duraibabu Terminated as Principal Financial Officer - SEC Filing
Sangamo Therapeutics ernennt Nikunj Jain zum Interim-Finanzchef
Reuters  ·  02-03 21:56
Sangamo Therapeutics ernennt Nikunj Jain zum Interim-Finanzchef
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial
Simply Wall St.  ·  02-01 13:19
Assessing Intellia Therapeutics (NTLA) Valuation After FDA Lifts Hold On MAGNITUDE-2 Trial
IBM, P&G, GameStop, Crispr, AGNC: Insider Moves Exposed
TIPRANKS  ·  01-31
IBM, P&G, GameStop, Crispr, AGNC: Insider Moves Exposed
Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis
TIPRANKS  ·  01-31
Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis
Cathie Wood’s ARK Investment buys 127K shares of Crispr Therapeutics today
TIPRANKS  ·  01-30
Cathie Wood’s ARK Investment buys 127K shares of Crispr Therapeutics today
Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Share Price Movements
Simply Wall St.  ·  01-29
Assessing CRISPR Therapeutics (CRSP) Valuation After Recent Share Price Movements
Is Intellia Therapeutics (NTLA) Now Pricing In Too Much After Its Recent Surge
Simply Wall St.  ·  01-29
Is Intellia Therapeutics (NTLA) Now Pricing In Too Much After Its Recent Surge
Intellia Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $25 From $15
THOMSON REUTERS  ·  01-28
Intellia Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $25 From $15
Top Executive Makes Bold Move With Fresh Crispr Therapeutics AG Stock Buy
TIPRANKS  ·  01-28
Top Executive Makes Bold Move With Fresh Crispr Therapeutics AG Stock Buy
Intellia Therapeutics Stock (NTLA) Pops as FDA Lifts Saftey Freeze on Nerve Disease Trial
TIPRANKS  ·  01-27
Intellia Therapeutics Stock (NTLA) Pops as FDA Lifts Saftey Freeze on Nerve Disease Trial

Introduction

Company Name.
BK4556
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--